Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bausch + Lomb Buy Vaults Valeant Into Consumer Eye Care Space

This article was originally published in The Tan Sheet

Executive Summary

Bausch + Lomb retains its name and becomes a division of Valeant in the $8.7 billion acquisition expected to close in the 2013 third quarter.

Advertisement

Related Content

Valeant Launches Lumify OTC Eye Drops With Vision Of Better Days As Bausch
Newly Approved OTC Eye Drop Could Boost Valeant Turnaround Outlook
Sanofi Should Take Note: As CEO Picks, Insiders Have History On Their Side
Rapid M&A Pushes Pharma Debt Higher And Credit Ratings Lower
Valeant Has Big Plans To Become A Big Pharma In Coming Year
Valeant Keeps Door Open For Consumer Products Acquisitions
Hi-Tech Deal Broadens Akorn Consumer Business
Firms Sift Eye Study Data For Benefit From Lutein And Zeaxanthin
Valeant Includes OTCs In Bid For Dramatic Growth By 2013
Bausch & Lomb OcuVite Line Extension Used In Natl. Eye Institute Study

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS106427

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel